Format

Send to

Choose Destination
Endocrinol Nutr. 2015 Apr;62(4):188-99. doi: 10.1016/j.endonu.2014.12.004. Epub 2015 Jan 27.

[Thyroid orbitopathy, an overview with special attention to the role of radiotherapy].

[Article in Spanish]

Author information

1
Servicio de Oncología, Queen Alexandra Hospital, Cosham, Reino Unido. Electronic address: santiagov06@gmail.com.
2
Servicio Endocrinología y Nutrición, CHUA, Albacete, España.
3
Servicio Oftalmología, CHUA, Albacete, España.
4
Servicio Física Médica, CHUA, Albacete, España.
5
UGC Oncología, Hospital Virgen de la Victoria, Málaga, España.
6
Fundación de Investigación Oftalmológica, Oviedo, España.
7
Servicio de Oftalmología, Hospital Cruz Roja Dos de Mayo, Barcelona, España.
8
Servicio de Oncología, Royal Preston Hospital, Fulwood, Reino Unido.

Abstract

Thyroid orbitopathy is the most prevalent non-thyroid symptom in Graves' syndrome. It has a high incidence and particularly affects young women. Smoking is clearly involved in its development and progress, and in its response to different treatments. This autoimmune condition usually has a benign course, independent from hyperthyroidism, but its severe, progressive forms represent a major therapeutic challenge. Clinical evaluation poses great difficulties, as there is no truly objective rating scale representing disease activity. New molecular or inflammation markers may prove to be useful in this regard. This review reports new findings about its pathophysiology and the different techniques used for treatment over time. Discussion particularly focuses on the immunomodulatory role of radiotherapy, as well as on its role together with corticosteroids.

KEYWORDS:

Corticoides; Corticosteroids; Graves ophthalmopathy; Irradiación; Irradiation; Oftalmopatía de Graves; Orbitopatía tiroidea; Radioterapia; Radiotherapy; Thyroid orbitopathy

PMID:
25637365
DOI:
10.1016/j.endonu.2014.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center